DIABETESpredict"

Sample collection: Swab (buccal epithelial cells) or EDTA tube (blood). **Results availability:** 15 working days.

BIBLIOGRAPHIC REFERENCES / DIET Araujo Almeida V et al. Comparison of Nutrigenomics Technology Interface Tools for Consumers and Health Professionals: A Sequential Explanatory Mixed Methods Investigation. Journal of Meidcal Internet Research, Genomics and Bioinformatics for Clinical Use. 2019, Vol 21, No 6. Johnston KL. Possible role for apple juice phenolic compounds in the acute modification of glucose tolerance and gastrointestinal hormone secretion in humans. Journal of the Science of Food and Agriculture, Volume 82, Issue 15, Pages 1800 - 1805, 23 Oct 2002. Knekt P et al. Flavonoid intake and risk of chronic diseases American Journal of Clinical Nutrition, Vol. 76, No. 3, 560-568, September 2002. 13th Congress of the International Society of Nutrigenetics/Nutrigenomics (ISNN). July 12-13, 2019, Cambridge, UK. Abete I et al. Recent Advances in Nutrigenetics and Nutrigenomics. Progress in Molecular Biology and Translational Science 2012, Deeb SS A Bro 120ke whether Both Journal of Clinical Nutrition, Vol. 76, No. 3, 560-568, September 2002. 13th Congress of the International Society of Nutrigenetics/Nutrigenomics (ISNN). July 12-13, 2019, Cambridge, UK. Abete I et al. Recent Advances in Nutrigenetics and Nutrigenomics. Progress in Molecular Biology and Translational Science, 2012. Deeb SS. A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, Iower body mass index and improved insulin sensitivity. Nat Genet 1998;20(3):284-287. Di Renzo L et al. Influence of FTO rs9939609 and Mediterranean diet on body composition and weight Ioss: a randomized clinical trial. Journal of Translational Medicine 2018, Vol 16, Article number: 308. Doo M. Obesity: Interactions of Genome and Nutrients Intake. Prev Nutr Food Sci. 2015 Mar; 20(1): 1–7. Fatema K et al. Glycemic, non-esteri-fied fatty acid (NEFA) and insulinemic responses to watermelon and apple in type 2 diabetic subjects. Asia Pac J Clin Nutr. 2003;12 Suppl:S53. Fu Z. Genistein Induces Pancreatic-Cell Proliferation through Activation of Multiple Signaling Pathways and Prevents Insulin Deficient Diabetes in Mice. Endocrinology 2010; 151(7):3026-3037. Fu Z. Genistein Induces Pancreatic -Cell Proliferation through Activation of Multiple Signaling Pathways and Prevents InsulinDefi-cient Diabetes in Mice. Endocrinology 2010; 151(7):3026-3037. Goni L et al. Future Perspectives of Personalized Weight Loss Interventions Based on Nutrigenetic, Epigenetic, and Metagenomic Data. The Journal of Nutrition, 2016, Vol 146, Issue 4, p 9055–912S. Hindy G et al. Role of TCF7L2 risk variant and dietary fibre intake on incident type 2 diabetes. Diabetologia 2012 Oct;55(10):2646-2654. Hindy G et al. Several type 2 diabetes. Subatologia 2012 Oct;55(10):2646-2654. Hindy G et al. Several type 2 diabetes. Subatologia 2012 Oct;55(10):2646-2654. Hindy G et al. Several type 2 diabetes. Subatologia 2012 Oct;55(10):2646-2654. Hindy G et al. Several type 2 diabetes. Subatologia 2012 Oct;55(10):2646-2654. Hindy G et doi:10.1186/s12889-019-6621-8. Popova P. Effect of gene-infestyle interaction on gestational diabetes risk. Oncotarget. 2017 Dec 19; 8(67): 112024–112035. Oi O et al. Weight-loss diets modify glucose-dependent insulinotropic polypeptide receptor rs2287019 genotype effects on changes in body weight, fasting glucose, and insulin resistance: the Preventing Overweight Using Novel Dietary Strategies trial. Am J Clin Nutr. 2012 Feb;95(2):506-13. Ramos-Lopez O et al. Guide for Current Nutrigenetic, Nutrigenomic, and Nutriepigenetic Approaches for Precision Nutrition Involving the Prevention and Management of Chronic Diseases Associated with Obesity. J Nutrigenet Nutrigenomic 2017;10:43-62. Ramos-Lopez O. Guide for Current Nutrigenetic, Nutrigenomic and Nutriepigenetic Approaches for Precision Nutrition Involving the Prevention Nutrigenomic, and Nutriepigenetic Approaches for Precision Nutrition Involving the Prevention and Management of Chronic Diseases Associated with Obesity. J Nutrigenet Nutrigenomics 2017; 10(1-2):43-62. Razquin C. The Mediterranean diet protects against waist circumference enlargement in 12Ala carriers for the PPARgamma gene: 2 years' follow-up of 774 subjects at high cardiovascular risk." British J Nutrition 2009; 102(5):672-9. Shoji T et al. Chronic administration

PHYSICAL ACTIVITY Hu FB. Globalization of diabetes: The role of diet, lifestyle, and genes. Diabetes Care 2011; 34(6): 1249-1257. Leonska-Duniec A et al. Genetic variants influencing effectiveness of exercise training programmes in obesity – an overview of human studies. Biol Sport. 2016 Sep; 33(3): 207–214. 13th Congress of the International Society of Nutrigenetics/Nutrigenomics (ISNN). July 12-13, 2019, Cambridge, UK. Antonio J et al. Assessment of the FTO gene isms (rs1421085, rs17817449 and rs9939609) in exercise-trained men and women: the effects of a 4-week hypocaloric diet. Journal of the International Society of Sports Nutrition

volume 16, Article number: 36 (2019). Deeb SS. A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 1998;20(3):284-287. Goni L et al. Future Perspectives of Personalized Weight Loss Interventions Based on Nutrigenetic, Epigenetic, and Metagenomic Data. The Journal of Nutrition, 2016, Vol 146, Issue 4,pPages 905S–912S. Karoly HC et al. Genetic Influences on Physiological and Subjective Responses to an Aerobic Exercise Session among Sedentary Adults. Journal of Cancer Epidemiology 2012, Article ID 540563. Liang Z et al. Genetic susceptibility, lifestyle intervention and glycemic changes among women with prior gestational diabetes. Clinical Nutrition 2019, https://doi.org/10.1016/j.clnu.2019.08.032.

SUPPLEMENTS 13th Congress of the International Society of Nutrigenetics/Nutrigenomics (ISNN). July 12-13, 2019, Cambridge, UK. Johnston KL. Possible role for apple juice phenolic compounds in the acute modification of glucose tolerance and gastrointestinal hormone secretion in humans. Journal of the Science of Food and Agriculture, Volume 82, Issue 15, Pages 1800 - 1805, 23 Oct 2002. Knekt P et al. Flavonoid intake and risk of chronic diseases American Journal of Clinical Nutrition, Vol. 76, No. 3, 560-568, September 2002. A scientific review: the role of chromium in insulin resistance. Diabetes Educ. 2004; Suppl:2:14. bete I et al. Recent Advances in Nutrigenetics and Nutrigenomics. Progress in Molecular Biology and Translational Science, 2012. 2012. Costello RB et al. Chromium supplements for glycemic control in type 2 diabetes: limited evidence of effectiveness. Nutrition Reviews, Volume 74, Issue 7, July 2016, Pages 455-468. Fatema K et al. Glycemic, non-esterified fatty acid (NEFA) and insulinemic responses to waterme-lon and apple in type 2 diabetic subjects. Asia Pac J Clin Nutr. 2003;12 Suppl:S53.Karel G. January 2018. The effect of Chromium in an amino acid lactate complex on glucose transport demonstration. demonstrating an extraordinary property of the lactate anion. Anc Sci Life. 2015 Jul-Sep;35(1):12-7. doi:10.4103/0257-7941.165623. Sinha SS. Effect of 6 Months of Meditation on Blood Sugar, Glycosylated Hemoglobin, and Insulin Levels in Patients of Coronary Artery Disease. Int J Yoga. 2018 May-Aug; 11(2): 122-128.

PHARMACOLOGY Eficacia terapéutica sulfonilureas: Schroner Z et al. Med Sci Monit. 2011; 17(7): CR392–CR396. Loganadan NK et al. The Pharmacogenomics Journal 2016, 16, 209-219. Li Q et al. Acta Pharmacologica 2016, 38, (1). Ren Q et al. Exp Clin Endocrinol Diabetes 2016; 124(03): 157-162. Ren Q et al. Diabetes Technology & Therapeutics 2016, Vol. 18, No. 9Y. Eficacia terapéutica de los inhibidores DPP-4: inhibitors: otthardova l et al. Diabetes Research and Clinical Practice 2017, Vol 130, pp 142-147. Eficacia terapéutica de repaglinida: Dai XP. Clin Exp Pharmacol Physiol. 2012 May; 39(5): 462-8. Eficacia terapéutica de rosiglitazone: Yu W et al. Clin Pharmacol Ther. 2011 Mar; 89(3): 437-42. Shin HD. J Clin Endocrinol Metab. 2010 Jan:95(1):445-9. Emiz S et al. Biochemia Medica 2013:23(2):154-71. M. Zulueta. Patia 2019. Integration of knowledge about Gene-Life interactions, clinical and experimental medicine and medical science; sine qua non know-how for inferring recommendations. Fischer A. KCNJ11 E23K affects diabetes risk and is associated with the disposition index: results of two independent German cohorts. Diabetes Care 2008;31(1):87-89. Giorgio S et al. The E23K variant of KCNJ11 encoding the pancreatic beta-cell adenosine 5'-triphosphate-sensitive potassium channel subunit Kiró.2 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetes. The Journal of clinical endocrinology and metabolism (2006). DOI: 10.1210/jc.2005-2323. Javorsky M.. European Journal of Internal Medicine. Volume 23, Issue 3, April 2012, Pages 245-249 KCNJ11 gene E23K variant and therapeutic response to sulfonylureas. Florez JC et al. Type 2 Diabetes-Associated Missense Polymorphisms KCNJ11 E23K and ABCC8 A1369S Influence Progression to Diabetes and Response to Interventions in the Diabetes Prevention Program. Diabetes 2007 Feb; 56(2): 531. Song J et al. KCNJ11, ABCC8 and TCF7L2 polymorphisms and the response to sulfonylurea treatment in patients with type 2 diabetes: a bioinformatics assessment. BMC Medical Genetics 2017, Vol. 18, Issue 1

DIABETESpredict[™] It is a registered trademark of Patia Europe S.L.[®]2024 All right reserved. Visit us at: www.patiadiabetes.com



For information about



Patia Europe S.L.® 2024 All right reserved. Paseo Mikeletegi 69, 20009 San Sebastián, España. contacto@patiadiabetes.com / +34 943 324 673 / www.patiadiabetes.com



Genomics for type 2 diabetes prevention & intervention

how to use, scan the OR code



From genetic risk assessment to diabetes clinical intervention

Patia has developed **DIABETES**predict[™], a forefront type 2 diabetes prevention and intervention platform.

DIABETESpredict[™] analyzes 16 genetic variants and provides genotype-informed recommendations, guiding the physician in clinical and lifestyle intervention.

DIABETES*predict*[™] algorithm integrates the individual's ancestry, family history, and anthropometric variables.

Clinical Indications

Type 2 diabetes genetic risk assessment, prevention and intervention in high risk individuals and T2D patients:

- Overweight and Obesity (BMI \geq 25 kg/m2 in adults; BMI 85% percentile in children).
- Sedentary lifestyle.
- High blood sugar level (≥100 mg/dl).
- High glycosylated hemoglobin (AlC \geq 5.7%).
- Type 2 diabetes family history.
- Clinical or family history of gestational diabetes mellitus.
- Type 2 diabetes patient to intervene with personalized
- treatment recommendations informed by the genotype.



DIABETESpredict[™]

| | Genes | Genotypes | |
|--|----------|-----------|---|
| RA | SLC16A11 | G | G |
| | INS-IGF2 | С | С |
| | HNF1A | G | G |
| | WFS1 | G | G |
| | SLC30A8 | Α | G |
| 0 | PPARG | С | С |
| Sample ID: 232790M | IGF2BP2 | Т | Т |
| Name: Sara López | CDKAL1 | Α | G |
| Gender: Female | ADCY5 | С | С |
| Age: 38 years old | JAZF1 | G | G |
| D.O.B: 30/03/1981 | HHEX/IDE | С | С |
| Ancestry: Western Europe | KCNJ11 | С | Т |
| Parental history DT2: Positive Boddy mass index: | KCNQ1 | С | С |
| 29 kg/m2 FRCV: HTA | TCF7L2 | С | Т |
| Other pathologies: Hyperglycemia | FTO | С | С |
| Stress: 2 Sleep: 6 | CDKN2A/B | С | Т |



production Decrease in the number of beta cells Reduces beta cell function

Predisposition to **type 2 diabetes**

Altered

insulin



Pancreas

Insulin resistance

Dyslipidemia

Genes: WFS1 / CDKN2A/B / INS-IGF2 / HNF1A / SLC3OA8 IGF2BP2 / CDKAL1 / ADCY5 / JAZF1 / HHEX/IDE / KCNJ11 KCNQ1 / TCF7L2

Genotype-informed recommendations

The **DIABETESpredict™** results report provides specific recommendations informed by the genotype, guiding the physician with precise steps for intervention. intervention.

Nutrition:

Informed by the TCF7L2 genotype, it's indicated a Mediterranean diet consisting largely of whole grains, lean proteins, olive oil, and moderate amounts of dairy products.

Due to the **CDKN2A/B** genotype grapes (high resveratrol content) and cod liver oil are recommended.

The diet should be rich in protein, reaching 60% of the daily intake and rich in eicosapentaenoic and docosahexaenoic acids (omega 3) in sardines, salmon, avocado.


Due to the WFS1 genotype, lentils (high in the flavonoid genistein) and apples with skin (rich in polyphenols) are recommended due to the FTO genotype.

Physical exercise:

It is recommended to practice aerobic exercise (4 days a week, 30 minutes), due to the CDKN2A/B and TCF7L2 genotype, combined with anaerobic exercise (3 days a week.

Benefits of DIABETESpredict[™]

- Identification of type 2 diabetes high risk individuals with a painless buccal DNA sample
- Guidance and motivation to implement and follow up healthy lifestyle personalized diets and physical activity
- Family cascade to enable early intervention
- Clase and continuous follow up of high risk individuals and patients with prediabetes or T2D Precision treatment of T2D patients





Genes: FTO / PPARG / SLC16A11

30 minutes) due to the FTO genotype. Pay attention to sleep hygiene and try to get 7-8 hours of restorative sleep at night.

Supplements:

DHA (omega 3), Vitamin A, Vitamin B complex, Potassium, Chromium. Probiotics.

Pharmacology:

Discuss with your physician the appropriateness of using Metformin after evaluation of HbA1c results, given the expected response to this drug due to the FTO genotype.

Consider sulfonylurea/meglitinide therapy given the expected response to these drugs due to expected response to these drugs due to the KCNQ1 genotype.

Other laboratory tests:

HbA1c / Fasting blood glucose / Lipid and triglyceride panel / Liver function panel / Ask about appetite and satiety / Investigate renal function, vision and hearing.

Genotype-informed recommendations

DIABETESpredict[™] results report offers specific recommendations based on genotype, guiding physicians with precise intervention guidelines.

Scientific reliability

Developed in collaboration with scientist and endocri-nologists at The Broad Institute of MIT and Harvard (Cambridge. USA) and The Massachusetts General Hospital (Boston, USA).

- Sci Rep 2019. 9(1):2748.
- Nature 2014. 506(7486):97-101.
- JAMA 2014.311(22):2305-2314.
- Nat Gene!. 2014. 46(3):234-244.
- Nat Gene!. 2012. 44(9):981-990.
- PLoS Gene!. 2015.11(12):e1005696